I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022
Lemzoparlimab combined with AZA showed encouraging clinical response in higher-risk MDS patients For patients received initial dose over 3 months, the ORR is 80.6% and for patients received initial dose over 6 months the ORR is 86.7%, CR rate 40% Lemzoparlimab does not require priming dosing with no unexpected safety signals...
First patient enrolled in Erectile Dysfunction prospective randomized study with SELUTION SLR
GENEVA, Switzerland, Sept. 10, 2022 /PRNewswire/ -- An 82-year-old Taiwanese man has become the first patient to be enrolled in the initial Erectile Dysfunction (ED) randomized clinical trial (RCT) involving SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon. MedAlliance_Image The PERFECT-SELUTION FIM (PElvic Revascularization For EreCTile dysfuction-SELUTION First-In-Man) study involves...
Redbud raises $10M in series A round as CRO focusing on science-driven clinical development
SHANGHAI, Sept. 10, 2022 /PRNewswire/ -- Redbud Medicine, the Delaware-headquartered contract research organization (CRO) announced on Monday following the completion of a series A round fundraising in which MING Bioventures Capital, Delian Capital and the existing Angel round investor Hongfeng Capital all participated. Legend Star led the Series pre-A round fundraising about less than a year ago. Redbud Medicine is a...
ESMO 2022 – Great oaks grow from small acorns: oncology is committed to doing its part for sustainability
PARIS, Sept. 10, 2022 /PRNewswire/ -- At ESMO 2022, 9-13 September, Paris, France, the premier cancer congress in Europe, which has gathered 28k participants from 167 countries, many discussions will be around sustainability, prevention and novel approaches which could soon become a reality in the clinic. Late-breaking results elucidate the link between air pollution and lung cancer in...
Prenetics Announces Second Quarter 2022 Financial Results and Raises Full Year Adjusted EBITDA Outlook
Revenue of US$51.7 million in the second quarter of 2022 Loss from operations of US$(17.9) million and adjusted EBITDA of US$6.5 million in the same period Raises full year adjusted EBITDA guidance to the range of US$35 million to US$45 million, with corresponding full year revenue guidance in the range of US$255 million to US$275 million Strong cash...
WuXi STA Opens a New Sterile Lipid Nanoparticle Formulation Facility to Enhance Global CRDMO Services for Customers
SHANGHAI, Sept. 9, 2022 /PRNewswire/ -- WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new sterile lipid nanoparticle (LNP) formulation development and manufacturing facility at its Wuxi city campus. Created in response to the increasing demand for complex injection dosage forms, this new facility marks the company's fast-growing parenteral formulation capabilities and is yet another...
111 Inc. Receives Unsolicited Preliminary Non-Binding Proposal to Acquire the Company
SHANGHAI, Sept. 9, 2022 /PRNewswire/ -- 111 Inc. ( "111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, today announced that its Board of Directors (the "Board") has received an unsolicited preliminary non-binding proposal letter (the "Proposal") dated September 9, 2022 jointly submitted by Dr. Gang Yu, co-founder and co-chairman of the Company, Mr....
Waterdrop Inc. Announces Second Quarter 2022 Unaudited Financial Results
BEIJING, Sept. 9, 2022 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial results for the second quarter ended June 30, 2022. Financial and Operational Highlights for the Second Quarter of 2022 Healthy and solid...
Antengene to Present at Upcoming Industry Conferences
SHANGHAI and HONG KONG, Sept. 9, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that members of the senior management team will participate and present at the following industry conferences...
MGI Celebrates Grand Opening of Its New State-of-the-Art Demo Lab in Japan
TOKYO, Sept. 9, 2022 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a global life science leader and innovator, announced today on its first day of IPO in China the grand opening of a new demonstration laboratory in Tokyo, Japan, enhancing Japanese customers' experience. MGI has been expanding the operations of its sub-subsidiary, MGI Tech Japan Co., Ltd., by establishing...
